Resultados da busca - Vanda Salutari

  • Mostrando 1 - 13 resultados de 13
Refinar Resultados
  1. 1
    Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status

    Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status por Angiolo Gadducci, Valentina Guarneri, Fedro A. Peccatori, Graziana Ronzino, Giuseppa Scandurra, Claudio Zamagni, Paolo Zola, Vanda Salutari

    Publicado em 2019
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors

    Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors por Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Rita Carbone, Giovanni Scambia, Domenica Lorusso

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  3. 3
    PARP Inhibitors Resistance: Mechanisms and Perspectives

    PARP Inhibitors Resistance: Mechanisms and Perspectives por Elena Giudice, Marica Gentile, Vanda Salutari, Caterina Ricci, Lucia Musacchio, Maria Vittoria Carbone, Viola Ghizzoni, Floriana Camarda, Francesca Tronconi, Camilla Nero, Francesca Ciccarone, Giovanni Scambia, Domenica Lorusso

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  4. 4
    Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

    Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? por Lucia Musacchio, Carlo María Cicala, Floriana Camarda, Viola Ghizzoni, Elena Giudice, Maria Vittoria Carbone, Caterina Ricci, Maria Teresa Perri, Francesca Tronconi, Marica Gentile, Vanda Salutari, Giovanni Scambia, Domenica Lorusso

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  5. 5
    The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

    The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial por Angeles Alvarez Secord, Sharyn N. Lewin, Colin G. Murphy, Sabrina Chiara Cecere, Arántzazu Barquín, Fernando Gálvez, Cara Mathews, G.E. Konecny, Isabelle Ray‐Coquard, A. Oaknin, Matthew Perez, A. Bonaventura, Elisabeth Diver, S-M. Ayuk, Y. Wang, Bradley R. Corr, Vanda Salutari

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial

    LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recur... por Mansoor Raza Mirza, Line Bjørge, Frederik Marmé, René dePont Christensen, Marta Gil-Martín, Annika Auranen, Beyhan Ataseven, María Jesús Rubio, Vanda Salutari, Bente Lund, IB Runnebaum, Andrés Redondo, Kristina Lindemann, Fabian Trillsch, M.P. Barretina Ginesta, Henrik Roed, Joan Løhndorf, G-B. Nyvang, Jalid Sehouli

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

    Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2... por Michael Friedlander, Val Gebski, Emma Gibbs, Lucy Davies, Ralph Bloomfield, Felix Hilpert, Lari Wenzel, Daniel Eek, Manuel Rodrigues, Andrew R. Clamp, Richard T. Penson, Diane Provencher, Jacob Korach, Tomasz Huzarski, Laura Vidal, Vanda Salutari, Clare L. Scott, Maria Ornella Nicoletto, Kenji Tamura, David Espinoza, Florence Joly, Éric Pujade-Lauraine

    Publicado em 2018
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

    Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 t... por Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna Maria Mosconi, Michele Orditura, Alba A. Brandes, Valentina Arcangeli, Pierluigi Benedetti Panici, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Francesco Raspagliesi, Giuseppa Maltese, Vanda Salutari, Caterina Ricci, Gennaro Daniele, Maria Carmela Piccirillo, Massimo Di Maïo, Ciro Gallo, Francesco Perrone

    Publicado em 2015
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

    Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study por Cristina Marchetti, Anna Fagotti, Robert Fruscio, Chiara Cassani, Lorena Incorvaia, M T Perri, Carolina Maria Sassu, Cristina Angela Camnasio, Emilia Giudice, Angelo Minucci, Marta Seca, Eloisa Arbustini, Laura Vertechy, Maria De Bonis, S M Boccia, Diana Giannarelli, Vanda Salutari, Mariagrazia Distefano, Maria Gabriella Ferrandina, Camilla Nero, Lucia Musacchio, Antonio Russo, Giovanni Scambia, D. Lorusso

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

    Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome por Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Claudia Carella, Paolo Scollo, Viola Ghizzoni, Francesco Raspagliesi, Marilena Di Napoli, E. Mazzoni, Cláudia Marchetti, Alice Bergamini, Michele Orditura, Giorgio Valabrega, Giovanni Scambia, Giuseppa Maltese, Elisabetta De Matteis, Cinzia Cardalesi, Vera Loizzi, Serena Maria Boccia, Emanuele Naglieri, Giuseppa Scandurra, Sandro Pignata

    Publicado em 2019
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

    Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial por Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, Antonella Savarese, Roberto Sorio, Enrico Breda, Vittorio Gebbia, Pietro Musso, Luigi Frigerio, Pietro Del Medico, Alessandra Lombardi, Antonio Febbraro, Paolo Scollo, Antonella Ferro, Stefano Tamberi, Alba A. Brandes, Alberto Ravaioli, Maria Rosaria Valerio, Enrico Aitini, D. Natale, Laura Scaltriti, Stefano Greggi, Carmela Pisano, Domenica Lorusso, Vanda Salutari, Francesco Legge, Massimo Di Maïo, Alessandro Morabito, Ciro Gallo, Francesco Perrone

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study

    Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study por Ignace Vergote, Larry J. Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia, Premal H. Thaker, David Cibula, Nicoletta Colombo, Jayanthi Lea, Antonio González-Martı́n, Jacob Korach, Jalid Sehouli, Bradley J. Monk, Viola Heinzelmann‐Schwarz, Regina Berger, Joseph Buscema, Susie Lau, Radosław Mądry, Hannelore Denys, Jessica Thomes Pepin, Vanda Salutari, Andrea Bagaméri, Antonio Ardizzoia, Stéphanie Henry, Sabrina Chiara Cecere, Martin Hruda, David A. Iglesias, Luís Manso, Ayelet Shai, David M. O’Malley

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Vali... por Eva‐Maria Willing, Claudia Vollbrecht, Christine Vössing, Peggy Weist, Simon Schallenberg, Johanna Herbst, Stefanie Schatz, Balázs Jóri, Guillaume Bataillon, Philipp Harter, Vanda Salutari, Antonio González‐Martín, Ignace Vergote, Nicoletta Colombo, Julia Roeper, Tobias Berg, Regina Berger, Bettina Kah, Trine Jakobi Noettrup, Markus Falk, Kathrin Arndt, Andreas Polten, Isabelle Ray‐Coquard, Franziska Selzam, Judith Pirngruber, Stefanie J. Schmidt, Michael Hummel, Markus Tiemann, David Horst, Jalid Sehouli, Éric Pujade-Lauraine, Katharina Tiemann, Elena Ioana Braicu, Lukas C. Heukamp

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: